It is very difficult to decide on right stock picks when the market is in the negative territory. When the market is volatile, the investors need to tread very cautiously to gain from the trades. Here are Brokerage Edelweiss' report on these 5 prospective shares:
The stock’s current valuation of 17.5x FY21E EPS, amid depressed earnings, offers an attractive entry in our view, said Edelweiss. Encouraging respiratory and biosimilar franchise may unlock value in the long run. "We maintain ‘BUY/SP’ with a target price of Rs 900."
"In this edition of Annual Report Insights, we analyse Lupin’s (LPC) FY19 annual report. FY19 was a tough year as US business revenues declined 12 percent and US subsidiaries reported a loss of Rs 9 billion vis-a-vis a profit of Rs 5billion in FY18," the brokerage said.
The profitability of the standalone business increased by 14 percent to Rs 15 billion.
Godrej Consumer Product (BUY)
GCPL’s domestic performance remains soft owing to weakness in household insecticides (HI; management has taken corrective action). Price war in hair colour is behind us which is positive, the brokerage said. "Growth in business coupled with margin expansion will be key going forward. Rolling forward the valuation, we arrive at revised target price of Rs 785. The stock is trading at 35.2x FY21E EPS. We maintain ‘BUY/SP’."
ACC’s Q2CY19 numbers defied consensus on two counts: 1) flat volumes versus decline estimate; and 2) earnings upgrade despite concerns of economic slowdown. The company looks set to benefit from industry positives of healthy cement prices and benign cost, Edelweiss report said. "Hence, we upgrade to ‘BUY/SP’ from ‘HOLD/SU’ with target price of Rs 1,846. At CMP, ACC trades at 10x CY20E EV/EBITDA."
Colgate Palmolive (HOLD)
The brokerage said it expected Colgate’s innovation funnel and brand investments to keep flowing, which should help it arrest market share loss. However, rising promotional intensity is a variable. "Maintain ‘HOLD/SP’ with a target price of Rs 1,356 (12-month forward). The stock is trading at an FY21E PE of 35.5x."
Sterlite Technologies (BUY)
Sterlite Technologies (Sterlite) reported strong 63.3 percent YoY revenue growth in Q1FY20. Higher contribution of product business (60 percent versus 52 percent QoQ) and sticky open financials (OF) realisation ($7/fkm) led to robust 22.6 percent EBITDA margin, up 500 bps QoQ. The brokerage said it believed that the Street was concerned about fall in OF realisation leading to lower product margin. However, Q1FY20 performance demonstrates Sterlite’s ability to manage OF realisation, and consequently product EBITDA margin, with superior product mix and cost control. "With more product capacity coming on stream and strong execution in services business, we believe Sterlite is well placed to sustain growth momentum. Maintain ‘BUY’ with revised target price of INR296 (INR285 earlier) as we roll forward to Q3FY21E."